This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
US Futures, European Stocks Rise After Fed Maintains Outlook DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating MT
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo... Our Logo
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Sector Update: Health Care MT
Transcript : Argenx SE, Q4 2023 Earnings Call, Feb 29, 2024
Argenx Q4 Loss Widens, Revenue Increases -- Shares Down Pre-Bell MT
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy CI
Wolfe Research Starts Argenx With Peer Perform Rating MT
Chart argenx SE
More charts
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
342 EUR
Average target price
439.4 EUR
Spread / Average Target
+28.47%
Consensus
  1. Stock Market
  2. Equities
  3. ARGX Stock
  4. News argenx SE
  5. Japanese Health Regulator Approves Argenx's Generalized Myasthenia Gravis Treatment